Assessment of patients' and physicians' compliance to an ACE inhibitor treatment based on urinary N-acetyl Ser-Asp-Lys-Pro determination in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) study

Diabetes Care

Volumn 29, Issue 6, 2006, Pages 1331-1336

  Azizi, Michel ^a,b,c   Ménard, Joël ^a,b,c   Peyrard, Séverine ^a,b,c   Lièvre, Michel ^d   Marre, Michel ^e   Chatellier, Gilles ^a,b,c  

^a INSERM   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HOSPICES CIVILS DE LYON   (France)

^e BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; RAMIPRIL; SERASPENIDE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CLUSTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MICROALBUMINURIA; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PROTEIN LOCALIZATION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; URINALYSIS;

AGED; ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OLIGOPEPTIDES; PATIENT COMPLIANCE; PHYSICIANS; PLACEBOS; PROTEINURIA;

EID: 33746418501     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-0255     Document Type: Article

References (24)

1. Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Menard J: Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 328:495-500, 2004
2. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 355:253-259, 2000
3. Cramer JA: A systematic review of adherence with medications for diabetes. Diabetes Care 27:1218-1224, 2004
4. Boudes P: Drug compliance in therapeutic trials: a review. Control Clin Trials 19:257-268, 1998
5. Jiang Q, Snapinn S, Iglewicz B: Calculation of sample size in survival trials: the impact of informative noncompliance. Biometrics 60:800-806, 2004
6. Haynes RB, Dantes R: Patient compliance and the conduct and interpretation of therapeutic trials. Control Clin Trials 8:12-19, 1987
7. Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296-1310, 2001
8. Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 353:487-497, 2005
9. Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet J-M, Lenfant M, Corvol P, Ménard J: Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 97:839-844, 1996
10. Azizi M, Ezan E, Reny J-L, Junot C, Wdziecazk-Bakala J, Gerineau V, Ménard J: Renal and metabolic clearance of AcSDKP during angiotensin converting enzyme inhibition in humans. Hypertension 33:879-886, 1999
11. Azizi M, Ezan E, Nicolet L, Grognet J-M, Ménard J: High plasma level of acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition. Hypertension 30:1015-1019, 1997
12. Struthers AD, MacFadyen R, Fraser C, Robson J, Morton JJ, Junot C, Ezan E: Nonadherence with angiotensin-converting enzyme inhibitor therapy: a comparison of different ways of measuring it in patients with chronic heart failure. J Am Coll Cardiol 34:2072-2077, 1999
13. Khattree R, Naik DN: Multivariate Data Reduction and Discrimination with SAS Software. Chichester, England, SAS Press and John Wiley, 2000
14. Silverman BW: Density Estimation for Statistics and Data Analysis. London, England, Chapman and Hall/CRC Press, 1986
15. Cramer JA, Scheyer RD, Mattson RH: Compliance declines between clinic visits. Arch Intern Med 150:1509-1510, 1990
16. Feinstein AR: On white-coat effects and the electronic monitoring of compliance. Arch Intern Med 150:1377-1378, 1990
17. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849-1861, 2005
18. ALLHAT-LLT investigators: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288:2998-3007, 2002
19. Clark WF, Garg AX, Blake PG, Rock GA, Heidenheim AP, Sackett DL: Effect of awareness of a randomized controlled trial on use of experimental therapy. JAMA 290:1351-1355, 2003
20. Manhem PJ, Ball SG, Morton JJ, Murray GD, Leckie BJ, Fraser R, Robertson JI: A dose-response study of HOE 498, a new non-sulphydryl converting enzyme inhibitor, on blood pressure, pulse rate and the renin-angiotensin-aldosterone system in normal man. Br J Clin Pharmacol 20:27-35, 1985
21. Urquhart J: The electronic medication event monitor: lessons for pharmacotherapy. Clin Pharmacokinet 32:345-356, 1997
22. Maenpaa H, Manninen V, Heinonen OP: Compliance with medication in the Helsinki Heart Study. Eur J Clin Pharmacol 42:15-19, 1992
23. Granger BB, Swedberg K, Ekman I, Granger CB, Olofsson B, McMurray JJ, Yusuf S, Michelson EL, Pfeffer MA: Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 366:2005-2011, 2005
24. Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S: Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med 143:89-99, 2005